Eligibility Rheumatoid Arthritis NCT01665430

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/= 18 years of age
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients who complete wa19926 core study (visit at week 104 and two follow-up telephone visits) and who may benefit from study drug treatment according to the investigator's assessment
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
no current or recent adverse event or laboratory finding preventing the use of the study drug dose of roactemra/actemra 8 mg/kg at baseline visit
Description

adverse event roactemra

Data type

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C3272237
receiving treatment on an outpatient basis
Description

outpatient

Data type

boolean

Alias
UMLS CUI [1]
C0029921
females of child-bearing potential must agree to use at least one adequate method of contraception as defined by protocol during the treatment period
Description

contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant women
Description

pregnant

Data type

boolean

Alias
UMLS CUI [1]
C0549206
patients who have prematurely withdrawn from the wa19926 study for any reason
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
treatment with any investigational agent or cell depleting therapies since last administration of study drug in the wa 19926 core study
Description

concomitant

Data type

boolean

Alias
UMLS CUI [1]
C2347852
treatment with an anti-tumor necrosis factor (tnf) or anti-interleukin (il)1 agent, or a t-cell costimulation modulator since the last administration of the study drug in the wa19926 core study
Description

anti-tumor necrosis factor therapy; t-cell costimulation modulator

Data type

boolean

Alias
UMLS CUI [1]
C0281481
UMLS CUI [2]
C2962759
immunization with a live/attenuated vaccine since the last administration of study drug in the wa19926 core study
Description

immunization; attenuated vaccine

Data type

boolean

Alias
UMLS CUI [1]
C0020971
UMLS CUI [2]
C0042211
diagnosis since visit at week 104 of the core wa19926 study of rheumatic autoimmune disease other than rheumatoid arthritis
Description

autoimmune disease rheumatic

Data type

boolean

Alias
UMLS CUI [1,1]
C0004364
UMLS CUI [1,2]
C3495832
diagnosis since visit at week 104 of the core wa19926 study of inflammatory joint disease other than rheumatoid arthritis
Description

inflammatory joint disease

Data type

boolean

Alias
UMLS CUI [1]
C0683381
evidence of serious uncontrolled concomitant disease or disorder
Description

concomitant disease

Data type

boolean

Alias
UMLS CUI [1]
C0243087
known active or history of recurrent infection
Description

infection recurrent

Data type

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C2945760
current liver disease as determined by investigator
Description

liver disease

Data type

boolean

Alias
UMLS CUI [1]
C0085605

Similar models

Eligibility Rheumatoid Arthritis NCT01665430

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
age
Item
adult patients, >/= 18 years of age
boolean
C0001779 (UMLS CUI [1])
Study Subject Participation Status
Item
patients who complete wa19926 core study (visit at week 104 and two follow-up telephone visits) and who may benefit from study drug treatment according to the investigator's assessment
boolean
C2348568 (UMLS CUI [1])
adverse event roactemra
Item
no current or recent adverse event or laboratory finding preventing the use of the study drug dose of roactemra/actemra 8 mg/kg at baseline visit
boolean
C0877248 (UMLS CUI [1,1])
C3272237 (UMLS CUI [1,2])
outpatient
Item
receiving treatment on an outpatient basis
boolean
C0029921 (UMLS CUI [1])
contraceptive methods
Item
females of child-bearing potential must agree to use at least one adequate method of contraception as defined by protocol during the treatment period
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
pregnant
Item
pregnant women
boolean
C0549206 (UMLS CUI [1])
Study Subject Participation Status
Item
patients who have prematurely withdrawn from the wa19926 study for any reason
boolean
C2348568 (UMLS CUI [1])
concomitant
Item
treatment with any investigational agent or cell depleting therapies since last administration of study drug in the wa 19926 core study
boolean
C2347852 (UMLS CUI [1])
anti-tumor necrosis factor therapy; t-cell costimulation modulator
Item
treatment with an anti-tumor necrosis factor (tnf) or anti-interleukin (il)1 agent, or a t-cell costimulation modulator since the last administration of the study drug in the wa19926 core study
boolean
C0281481 (UMLS CUI [1])
C2962759 (UMLS CUI [2])
immunization; attenuated vaccine
Item
immunization with a live/attenuated vaccine since the last administration of study drug in the wa19926 core study
boolean
C0020971 (UMLS CUI [1])
C0042211 (UMLS CUI [2])
autoimmune disease rheumatic
Item
diagnosis since visit at week 104 of the core wa19926 study of rheumatic autoimmune disease other than rheumatoid arthritis
boolean
C0004364 (UMLS CUI [1,1])
C3495832 (UMLS CUI [1,2])
inflammatory joint disease
Item
diagnosis since visit at week 104 of the core wa19926 study of inflammatory joint disease other than rheumatoid arthritis
boolean
C0683381 (UMLS CUI [1])
concomitant disease
Item
evidence of serious uncontrolled concomitant disease or disorder
boolean
C0243087 (UMLS CUI [1])
infection recurrent
Item
known active or history of recurrent infection
boolean
C3714514 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
liver disease
Item
current liver disease as determined by investigator
boolean
C0085605 (UMLS CUI [1])